Skip to main content
Fig. 6 | Arthritis Research & Therapy

Fig. 6

From: The pan-PPAR agonist lanifibranor reduces development of lung fibrosis and attenuates cardiorespiratory manifestations in a transgenic mouse model of systemic sclerosis

Fig. 6

Schematic describing effects of pan-PPAR agonism on pulmonary fibrosis and pulmonary hypertension in TβRII∆k-fib mice. Transgenic mice replicate many features of human systemic sclerosis. The phenotypes of pulmonary fibrosis and pulmonary hypertension are exacerbated by the administration of bleomycin and SU5416, respectively. PPAR agonism alleviates pulmonary fibrosis and prevents development of right ventricular hypertrophy in response to the pulmonary hypertension in this model

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us